Himuka AM
Develops adrenomedullin-based pharmaceutical candidates HM101 and HM201 and advances them through Phase 1 clinical trials and license agreements
Develops adrenomedullin-based pharmaceutical candidates including HM101 and HM201 and advances them through clinical development including Phase 1 trials. Serves pharmaceutical licensing partners and the healthcare sector that require new therapeutic candidates. Operates as a research and development biopharmaceutical company that conducts clinical trials in Australia and enters license agreements to advance its pipeline.
Key features
- Adrenomedullin-based drug development
- HM101 license agreement
- HM201 Phase 1 clinical trial
Social posts
- No social media activity detected
GTM channels
- No GTM activity detected
ICP
- Healthcare providers
- Enterprises
- Government public sector